Filing Flows › Bristol Myers Squibb (BMY) › Q1 2025
Bristol Myers Squibb (BMY) Q1 2025 earnings results (first quarter 2025)
10-Q filed Apr 24, 2025
Bristol Myers Squibb (BMY) reported revenue of $11.2B for the first quarter 2025 (Q1 2025), -6% from a year earlier and -9% from the quarter before. Operating margin was 26.5%, net earnings $2.5B (22.0% of revenue).
Bristol Myers Squibb, Q1 2025: revenue $11.2B (-6% year over year), operating margin 26.5%, net earnings $2.5B, operating cash flow $2.0B. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $11.2B | -9% | -6% |
| Operating profit | $3.0B | 17× | — |
| Net earnings | $2.5B | 32× | — |
| Operating cash flow | $2.0B | -56% | -31% |
| Free cash flow | $1.7B | -58% | -34% |
What changed
Revenue was $11.2B in Q1 2025, down 6% year over year and down 9% from the previous quarter. Growth Portfolio was the largest line at 50% of revenue. Revlimid lost $0.73B year over year (down 44%), 110% of the total change.
Operating profit was $3.0B, a 26.5% margin (up 123.6 points year over year). Total costs fell 65% while revenue fell 6%. Net earnings were $2.5B. The effective tax rate was 17.1%.
Operating cash flow was $2.0B (down 31% year over year), 79% of net earnings. Non-cash charges added back $1.0B of depreciation and amortization and $0.14B of share-based compensation. Working capital and other items used $1.7B. Capital expenditures of $0.26B left free cash flow of $1.7B.
Questions
What was Bristol Myers Squibb's revenue in the first quarter 2025?
Bristol Myers Squibb (BMY) reported revenue of $11.2B for the first quarter 2025 (Q1 2025), -6% from a year earlier and -9% from the quarter before.
Was Bristol Myers Squibb profitable in the first quarter 2025?
Operating profit was $3.0B (26.5% of revenue) and net earnings $2.5B.